Actinic cheilitis

Summary

Actinic cheilitis (MONDO:0043300) is a disease and 10 clinical trials. Top therapeutic interventions include imiquimod, aminolevulinic acid hydrochloride, and dexpanthenol. A subtype of cheilitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	actinic cheilitis
Mondo ID	MONDO:0043300
MeSH	C535669
ICD-11	436658980
NCIT	C183562
SNOMED CT	46795000
UMLS	C0267026
MedGen	75625
Is cancer (heuristic)	no

Also known as: actinic cheilitis · actinic cheilosis

Disease family

This is a subtype of cheilitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › mouth disorder › lip disorder › cheilitis › actinic cheilitis

Related subtypes (2): angular cheilitis, Melkersson-Rosenthal syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	4
PHASE1	2
Not specified	2
PHASE1/PHASE2	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00849992	PHASE4	COMPLETED	Treatment Study for Actinic Cheilitis Comparing Imiquimod 5% and Photodynamic Therapy
NCT00868088	PHASE4	COMPLETED	Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip
NCT02409732	PHASE4	COMPLETED	Photodynamic Therapy (PDT) With Levulan and Blue Light for the Treatment of Actinic Cheilitis
NCT04744103	PHASE4	WITHDRAWN	Trichloroacetic Acid as a Topical Treatment for Actinic Cheilitis
NCT03452566	PHASE1/PHASE2	WITHDRAWN	Evaluation of Ingenol Mebutate for Actinic Cheilitis Treatment
NCT03990636	PHASE2	UNKNOWN	Photodynamic Therapy With Metil 5-aminolevulinate for Actinic Cheilitis - Phase 2 Clinical Trial
NCT02198469	PHASE1	COMPLETED	Study of Methyl Aminolaevulinate Photodynamic Therapy With and Without Er:YAG Laser in Actinic Cheilitis
NCT04219358	PHASE1	TERMINATED	Topical Application of Imiquimod Gel at Different Concentrations in Actinic Cheilitis
NCT06321003	Not specified	RECRUITING	SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography
NCT03224715	Not specified	WITHDRAWN	Actinic Cheilitis Pre-Treated With DNA Repair Enzyme Cream

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
IMIQUIMOD	4	2
AMINOLEVULINIC ACID HYDROCHLORIDE	4	1
DEXPANTHENOL	4	1